Does cellular iron dysregulation play a causative role in Parkinson's disease?

被引:110
作者
Kaur, D [1 ]
Andersen, J [1 ]
机构
[1] Buck Inst Aging Res, Novato, CA 94945 USA
关键词
Parkinson's disease; oxidative stress; iron; iron regulatory proteins; mitochondrial dysfunction; alpha-synuclein;
D O I
10.1016/j.arr.2004.01.003
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Selective dopaminergic cell loss in Parkinson's disease is correlated with increased levels of cellular iron. It is still hotly debated as to whether the increase in iron is an upstream event which acts to promote neurodegeneration via formation of oxidative stress or whether iron accumulates as a by-product of the neuronal cell loss. Here we review evidence for loss of iron homeostasis as a causative factor in disease-associated neurodegeneration and the primary players which may be involved. A series of recent studies suggest that iron regulatory proteins (IRPs) coordinate both cellular iron levels and energy metabolism, both of which are disrupted in Parkinson's disease (PD) and may in turn contribute to increased levels of oxidative stress associated with the disease. Iron has also been recently been implicated in promotion of alpha-synuclein aggregation either directly or via increasing levels of oxidative stress suggesting an important role for it in Lewy body formation, another important hallmark of the disease. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:327 / 343
页数:17
相关论文
共 99 条
[21]  
Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO
[22]  
2-4
[23]   STUDIES ON PARKINSONS DISEASE INCLUDING X-RAY FLUORESCENT SPECTROSCOPY OF FORMALIN FIXED BRAIN TISSUE [J].
EARLE, KM .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1968, 27 (01) :1-+
[24]   Iron regulatory proteins and the molecular control of mammalian iron metabolism [J].
Eisenstein, RS .
ANNUAL REVIEW OF NUTRITION, 2000, 20 :627-662
[25]   Familial aggregation of Parkinson's disease - A population-based case-control study in Europe [J].
Elbaz, A ;
Grigoletto, F ;
Baldereschi, M ;
Breteler, MM ;
Manubens-Bertran, JM ;
Lopez-Pousa, S ;
Dartigues, JF ;
Alperovitch, A ;
Tzourio, C ;
Rocca, WA .
NEUROLOGY, 1999, 52 (09) :1876-1882
[26]   H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties [J].
Epsztejn, S ;
Glickstein, H ;
Picard, V ;
Slotki, IN ;
Breuer, W ;
Beaumont, C ;
Cabantchik, ZI .
BLOOD, 1999, 94 (10) :3593-3603
[27]   Description of Parkinson's disease as a clinical syndrome [J].
Fahn, S .
PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON, 2003, 991 :1-14
[28]   Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease [J].
Faucheux, BA ;
Martin, ME ;
Beaumont, C ;
Hunot, S ;
Hauw, JJ ;
Agid, Y ;
Hirsch, EC .
JOURNAL OF NEUROCHEMISTRY, 2002, 83 (02) :320-330
[29]   H ferritin knockout mice:: a model of hyperferritinemia in the absence of iron overload [J].
Ferreira, C ;
Santambrogio, P ;
Martin, ME ;
Andrieu, V ;
Feldmann, G ;
Hénin, D ;
Beaumont, C .
BLOOD, 2001, 98 (03) :525-532
[30]   Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits [J].
Fredriksson, A ;
Schröder, N ;
Eriksson, P ;
Izquierdo, I ;
Archer, T .
PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) :97-105